{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-021359","form_type":"8-K","ticker":"VKTX","cik":"0001607678","company_name":"Viking Therapeutics, Inc.","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.646702+00:00","generated_at":"2026-06-15T04:11:13.063841+00:00","sec_items":["5.03","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"high","headline":"Viking Therapeutics amends bylaws for universal proxy rules and enhanced disclosure","bullets":["Board approved amended and restated bylaws effective May 9, 2023.","Amendments require stockholders nominating directors to comply with SEC Rule 14a-19 universal proxy rules.","Enhanced disclosure requirements for director nominations and business proposals by stockholders.","Stockholders soliciting proxies must use a proxy card color other than white; white reserved for Board.","Eliminated requirement to make stockholder list available during meetings, consistent with Delaware law."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-021359","json":"https://secwatch.observer/filing/0000950170-23-021359.json","markdown":"https://secwatch.observer/filing/0000950170-23-021359.md","text":"https://secwatch.observer/filing/0000950170-23-021359.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1607678/000095017023021359/0000950170-23-021359-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1607678/000095017023021359/vktx-20230509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T04:11:13.063841+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c6eec1275a43bc0739e00336b95bc158bf548d95","claim":"Viking Therapeutics, Inc.: Amended and restated bylaws to address universal proxy rules, including compliance with Rule 14a-19, enhanced disclosure requirements, and other conforming changes (effective 2023-05-09).","evidence_excerpt":"On May 9, 2023, the Board of Directors (the “Board”) of Viking Therapeutics, Inc. (the “Company”) approved and adopted an amendment and restatement of the Company’s amended and restated bylaws (as so amended and restated, the “Amended and Restated Bylaws”), effective as of such date.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1607678/000095017023021359/0000950170-23-021359-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2023-05-09"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}